Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $6.96M | $13.4M | $18.0M | $3.13M | $20.7M | $37.0K | $85.2M |
| Revenue growth | — | 92.0% | 35.0% | -82.7% | 562.3% | -99.8% | 230194.6% |
| Operating income | -$50.8M | -$56.7M | -$71.3M | -$110M | -$113M | -$188M | -$160M |
| Operating margin | -729.4% | -424.0% | -395.5% | -3516.5% | -544.6% | -507678.4% | -187.2% |
| Net income | -$49.3M | -$56.7M | -$71.3M | -$107M | -$101M | -$161M | -$140M |
| Net margin | -708.4% | -424.3% | -395.4% | -3435.4% | -486.6% | -434778.4% | -164.4% |
| EPS (diluted) | -$9.59 | -$8.82 | -$2.57 | -$3.32 | -$2.58 | -$2.98 | -$2.42 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$36.7M | -$50.9M | -$69.1M | -$86.7M | -$75.8M | -$135M | -$109M |
| Capital expenditures | $3.20M | $1.00M | $9.11M | $11.5M | $2.77M | $3.79M | $536K |
| Free cash flow | -$39.9M | -$51.9M | -$78.2M | -$98.2M | -$78.6M | -$138M | -$110M |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $49.7M | $277M | $153M | $52.4M | $249M | $149M | $60.2M |
| Total assets | $58.2M | $288M | $353M | $262M | $340M | $560M | $567M |
| Total liabilities | $28.2M | $31.9M | $34.4M | $30.5M | $32.1M | $49.8M | $61.0M |
| Shareholders' equity | -$73.0M | $256M | $319M | $231M | $308M | $511M | $506M |
| Retained earnings | -$79.0M | -$136M | -$207M | -$314M | -$415M | -$576M | -$716M |
| Shares (wtd avg diluted) | 5.18M | 26.7M | 27.7M | 32.4M | 39.1M | 53.9M | 57.9M |
Every figure is extracted from 4D Molecular Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.